Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was terminated due to insufficient subject enrollment and very slow enrollment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region. This study will also record encountered tumor subtype and stage and the instituted pharmacological treatments, as well as assess the clinical outcomes of treatments.
Patients will be followed up to 30 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment naïve patients with CLL | |||
| Treatment naïve patients with iNHL | |||
| Relapsed/refractory patients with CLL | |||
| Relapsed/refractory patients with iNHL |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients on different types of pharmacological regimen for treatment of Chronic Lymphocytic Leukaemia (CLL) or Indolent Non Hodgkin's Lymphoma (iNHL) | Types of combination treatment (including but not limited to R-CHOP [rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone] , FCR [fludarabine, cyclophosphamide, rituximab], COP [cyclophosphamide, doxorubicin, prednisone], BR [bendamustine, rituximab], etc.) will be collected in treatment-naïve and relapsed patients. Data to be described as percentage of patients on each regimen. | Baseline, 1 year and 2 years after baseline (up to 30 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Duration of response | up to 30 months | |
| Overall survival | up to 30 months | |
| Progression free survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients are from the MENA region, and will be selected from sites that are considered clinical centres of excellence in the region.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Astellas Pharma International B.V. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site JO96201 King Abdullah University Hospital | Irbid | Irbid Governorate | 22110 | Jordan | ||
| Site KW96501 Kuwait Cancer Control Center |
Not provided
Not provided
Not provided
Not provided
| up to 30 months |
| Number of subjects in complete remission | up to 30 months |
| Number of subjects in partial remission | up to 30 months |
| Disease type and staging | up to 30 months |
| Clinical responses | Relapses, response or non-response to treatment | up to 30 months |
| Safety as assessed by adverse events | up to 30 months |
| CLL specific variable: Histology | Proportion of different subtypes in CLL: (1) histologically indolent CLL (HIC), defined as morphologically typical CLL with no histologic features of progression or transformation such as increased large cells, large confluent proliferation centers, or high proliferation rate; (2) CLL with histological features of intermediate aggressiveness histologically aggressive CLL [HAC]) (3) Richter's syndrome. Data to be described as percentage. | up to 30 months |
| iNHL specific variables: Histology | Proportion of different subtypes in iNHL will be presented. Data to be described as percentage. | up to 30 months |
| Health-related quality of life variables | Using EQ-5D questionnaire, including a visual analog scale (dimensions): mobility, self-care, usual activities, pain/discomfort, anxiety/depression | up to 30 months |
| CLL specific variable: Rai/Binet staging systems | Percentage of patients in the different stages. | up to 30 months |
| CLL specific variable: Clinically relevant biomarker status | Includes immunoglobulin heavy chain variable (IgHV) status, ZAP-70 (70-kDa zeta-associated protein), receptor status (including CD20), cytogenetics (6q, 11q, 13q, and 17p deletion or monosomy, trisomy 12 ). Percentages will be presented for the clinically relevant biomarker status. | up to 30 months |
| iNHL specific variables: Ann Arbor staging classification | Percentage of patients in the different stages. | up to 30 months |
| iNHL specific variables: Clinically relevant biomarker status | Includes receptor status (including CD20). Percentages will be presented for the clinically relevant biomarker status. | up to 30 months |
| Ash Shuwaykh |
| Shuwaikh |
| 70653 |
| Kuwait |
| Site Hammoud Hospital University Medical Center | Beirut | Beirut | 1600 | Lebanon |
| Site Hotel Dieu De France | Beirut | Beirut | 166830 | Lebanon |
| Site OM96801 Sultan Qaboos University Hospital | Muscat | Muḩāfaz̧at Masqaţ | 123 | Oman |
| Site Hamad Medical Coorporation, National Center for Cancer Care and Research, Al Amal Hospital | Doha | Baladiyat ad Dawhah | 3050 | Qatar |
| Site SA96601 Aseer Central Hospital | Abhā | 'Asir Region | 61421 | Saudi Arabia |
| Site AE97101 Sheikh Khalifa Medical City | Abu Dhabi | Abu Dhabi Emirate | 51900 | United Arab Emirates |
| ID | Term |
|---|---|
| D015448 | Leukemia, B-Cell |
| ID | Term |
|---|---|
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided